Skip to main content

Table 1 Patient and lesion characteristics

From: Diffusion tensor imaging for characterizing tumor microstructure and improving diagnostic performance on breast MRI: a prospective observational study

Patients (N = 194) Value
Age, years 51 (23–83)
Menopausal status
 Pre 93 (47.9)
 Post 101 (52.1)
Indication
 New cancer 126 (64.9)
 Screening/problem solving 68 (35.1)
Breast density
 Fatty 5 (2.6)
 Scattered fibroglandular 47 (24.2)
 Heterogeneously dense 108 (55.7)
 Dense 34 (17.5)
Background parenchymal enhancement
 Minimal 58 (29.9)
 Mild 79 (40.7)
 Moderate 37 (19.1)
 Marked 20 (10.3)
Lesions per patient
 1 lesion 157 (80.9)
 2 lesions 30 (15.5)
 3 lesions 7 (3.6)
Lesions (N = 238)
Largest diameter, cm
 < 1.0 cm 98 (41.2)
 1.0–1.9 cm 71 (29.8)
 2.0–3.9 cm 38 (16.0)
 ≥ 4.0 cm 31 (13.0)
Type
 Mass 135 (56.7)
 NMLE 99 (41.6)
 Focus 4 (1.7)
Delayed phase kinetics(most suspicious)
 Persistent 6 (2.5)
 Plateau 34 (14.3)
 Washout 198 (83.2)
BI-RADS
 4 218 (91.6)
 5 20 (8.4)
Histopathology
 Malignant 95 (39.9)
 Benign 143 (60.1)
Cancer subtype (n = 90*)
 Invasive 73 (81.1)
 DCIS 17 (18.9)
Benign subtype (n = 143)
 Fibroadenoma 25 (17.5)
 Fibrocystic changes 21 (14.7)
 Fibrosis 14 (9.8)
 Usual ductal hyperplasia 12 (8.4)
 Apocrine metaplasia 11 (7.7)
 Lobular neoplasia (LCIS, ALH) 9 (6.3)
 Papilloma 9 (6.3)
 Adenosis 8 (5.6)
 Pseudoangiomatous stromal hyperplasia 6 (4.2)
 Inflammation 5 (3.5)
 Atypical ductal hyperplasia 4 (2.8)
 Fibroadenomatoid change 4 (2.8)
 Normal breast tissue 4 (2.8)
 Other miscellaneous 11 (7.7)
  1. Values are median (range) or no. (%)
  2. NME non-mass enhancement, DCIS ductal carcinoma in situ, LCIS lobular carcinoma in situ, ALH atypical lobular hyperplasia
  3. *Five malignancies did not have a cancer subtype available